Compare SHMD & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | IFRX |
|---|---|---|
| Founded | 1864 | 2007 |
| Country | Germany | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 225.5M |
| IPO Year | 2023 | 2017 |
| Metric | SHMD | IFRX |
|---|---|---|
| Price | $2.12 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.41 |
| AVG Volume (30 Days) | 821.2K | ★ 1.1M |
| Earning Date | 11-25-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.82 | N/A |
| Revenue Next Year | $48.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.09 | $0.80 |
| 52 Week High | $10.65 | $2.95 |
| Indicator | SHMD | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 31.08 |
| Support Level | $2.09 | $0.81 |
| Resistance Level | $3.65 | $2.44 |
| Average True Range (ATR) | 0.25 | 0.15 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 2.83 | 3.12 |
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.